佩小姐的奇幻城堡

China's pharmaceutical industry sees accelerated innovation breakthroughs in H1_我的网站

一 |     (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed.    China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval.    A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country.    Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category.    This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading.     At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly.    To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong.    The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions.    In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total.        (By Tang Yuxian)                    。    印度女游客在吉隆坡街道坠入地洞事件，引起民众对当地基础设施安全的担忧。不过，有计划飞往吉隆坡的狮城旅客表示，不会因此取消原定行程。从事传播媒体业的29岁扎希尔（Zahir）告诉新传媒英文新闻网CNA，他接下来将前往八打灵再也（Petaling Jaya）参加一场活动，原本也计划同未婚妻到吉隆坡游玩，包括走访近日发生地陷的印度回教堂路（Jalan Masjid India）。

本地旅客：或放弃走访事故区域

    不过，由于当地接连发生地陷事故，他坦言会考虑打消走访印度回教堂路的念头。“如果只有出现一个地洞，我们可能不会当成一回事，但在如此短时间内出现了两次地陷事故，而且两个地洞距离如此相近，说明那里存在很大的潜在安全问题。”扎希尔也指出，地陷与其他结构性问题不同。“如果你看到路面破损，你可以直接避开，但地陷不行，你不知道什么时候会发生，也无法做准备。”一名48岁印度女游客上周五（本月23日）在印度回教堂路人行道上行走时，因为路面突然塌陷而坠入八米深坑，至今下落不明。事故发生六天后，距离第一个地陷地点50米外，出现了第二个地洞。此外，吉隆坡市甘榜格灵芝（Kampung Kerinchi）班台柏迈路（Jalan Pantai Permai）一处的人行道，本月26日也发生地陷。对此，另一名已计划前往吉隆坡的旅客——68岁退休人士赛义德·纳西尔则表示，，由于会担心当地再发生地陷，因此会避免前往那些地点。不过，他也提到，当地政府采取了必要行动，并封锁了事发路段，有助缓解他的担忧。坐落在文礼购物中心内的两家巴士业者昨天（29日）受询时指出，公司并没有接获任何取消订票的通知。记者查看售票平台BusOnlineTicket和Easybook时也发现，今明两天前往吉隆坡的大部分巴士也已坐满。

吉隆坡旅游协会：事故未影响当地旅游业

    吉隆坡旅游协会主席赛义德·阿扎尔·赛义德·纳齐尔（Syed Azhar Syed Nadzir）受访时认为，地陷事故并没有对该市旅游业带来任何影响，但预计前往印度回教堂地区的旅客将减少。“我们在预订平台上没有看到任何取消预订的情况。现在是暑假，被认为是旺季，我们相信所有预订都会保留。”他也指出，当地偶尔会发生山体滑坡等事件，但旅客向来都不会因此避免到当地游玩。马来西亚入境旅游协会主席乌达尼斯（Uzaidi Udanis）同样透露，地陷发生后，预订量并没有减少。“我每天都与外国同行接触，但关于这一事件的讨论并不多。”

酒店业者：顾客纷纷取消订房

    然而，事发地区的酒店业者纷纷表示，接获不少顾客取消订房。坐落在地洞附近的酒店宫殿酒店（Palace Hotel）职员指出，该酒店事后都接到了来自当地和外国顾客取消订房的通知，平日的入住率下跌了20%。“生意不太好，因为有很多订单被取消，尤其是上个周末，也就是公共假期的时候。我们也不知道这样的情况还会持续多久。”另一家廉价酒店MK Inn则表示，目前还无法确定此次事件的影响，但已经看到一些顾客开始取消订房的情况。工作人员透露，该酒店很大程度上依赖散客，但目前到该区走动的人并不多。

Current article:http://dlu8a2.zanjionglangzhaizhizaxiying.buzz/list_cl58r/84n.html

Published on:17:38:16